# Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer

> **NCT03635021** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)** · enrollment: 419 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** FOLFOX regimen
- **DRUG:** Panitumumab
- **DRUG:** Bevacizumab
- **DRUG:** FOLFIRI regimen

## Key facts

- **NCT ID:** NCT03635021
- **Lead sponsor:** Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-15
- **Primary completion:** 2025-06-28
- **Final completion:** 2025-06-28
- **Target enrollment:** 419 (ESTIMATED)
- **Last updated:** 2024-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03635021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03635021, "Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03635021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*